Navigation Links
Algeta Demonstrates Targeted Cancer-killing Potential of Novel,Alpha Particle Linked Antibodies in Leading Medical Journal Blood

Preclinical Studies Show 227Th-rituximab More Effective at Killing CD20-Positive Lymphoma Cells Than 90Y-tiuxetan-ibritumomab (Zevalin)

OSLO, Norway, 14 June 2007 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, announces that a research paper showing the potential of its TH-1 technology for targeted cancer therapy has been published by the leading medical journal, Blood, the official journal of the American Society of Hematology (ASH).

Algeta's TH-1 technology links Thorium-227, which emits alpha particles, to cancer-targeting molecules such as antibodies. Alpha-emitting radionuclides are of considerable interest in the treatment of cancer as they are highly destructive to tumour cells but have very short range. Linking this radionuclide to tumour-seeking molecules creates a conjugate with the potential to specifically seek and destroy cancers while leaving surrounding healthy tissues undamaged.

The Blood paper describes how researchers from the Norwegian Radium Hospital (Oslo) in collaboration with Professor Oliver Press at the Fred Hutchison Cancer Research Center (Seattle, USA) and Algeta have linked Thorium-227 to the monoclonal antibody rituximab to create 227Th-rituximab and demonstrated its potent anti-tumour effects.

Rituximab binds to a specific molecule on the cancer cell surface called CD20 and is marketed in USA as Rituxan® by Genentech and Biogen-Idec for the treatment of certain types of non-Hodgkin's lymphoma (NHL) and rheumatoid arthritis, and as MabThera® by Roche for the treatment of certain types of NHL. Rituximab-based therapies generated global sales of nearly $6 billion in 2006.

In in vitro studies 227Th-rituximab killed CD20-positive lymphoma cells at low doses (Bq/ml) while in preclinical models, a single injection of 227Th-rituximab induced complete tumor regression in up to 60% of tumours without apparent toxicity.

<
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Algeta to Present Phase II Clinical Study Data for Alpharadin in Prostate Cancer at ASCO
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
9. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
10. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
11. Lpath Demonstrates First-in-Class AMD Results With Its Lead Drug Candidate, Sphingomab
Post Your Comments:
(Date:5/22/2015)... LONDON , May 22, 2015 ... early phase clinical research unit with a worldwide ... respected for its frequent publications in peer reviewed ... and European stakeholders and regulators in discussions about ... results.      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , ...
(Date:5/22/2015)... -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD ) ("Nepstar" ... China based on the number ... Mr. Fuxiang Zhang as the Company,s Chief ... Rebecca Yingnan Zhang has been appointed as Chief ... immediately. Meanwhile, Ms. Zhang resigned from the position as ...
(Date:5/21/2015)... , May 21, 2015  When ... along the side of his neck, he ... took a couple weeks off from weight ... go away.                               A ... 26, was referred to Michel Kliot, ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4
... 2012  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... fourth quarter and full year financial results for the ... 2012 after market close. PDL,s management will host a ... Eastern Time to discuss the financial results. ...
... 2012  ViroPharma Incorporated (NASDAQ: VPHM ) today ... orphan drug Plenadren ® (hydrocortisone, modified release tablet) ... Metabolism (JCEM), a leading scientific journal for endocrinology. Plenadren ... adrenal insufficiency in adults. The authors described ...
Cached Medicine Technology:PDL BioPharma to Announce Fourth Quarter and Full Year 2011 Financial Results on February 23, 2012 2Pivotal Data Demonstrating Efficacy of Plenadren® (Hydrocortisone, Modified Release Tablet) in Adrenal Insufficiency Published in the Journal of Clinical Endocrinology and Metabolism 2Pivotal Data Demonstrating Efficacy of Plenadren® (Hydrocortisone, Modified Release Tablet) in Adrenal Insufficiency Published in the Journal of Clinical Endocrinology and Metabolism 3Pivotal Data Demonstrating Efficacy of Plenadren® (Hydrocortisone, Modified Release Tablet) in Adrenal Insufficiency Published in the Journal of Clinical Endocrinology and Metabolism 4Pivotal Data Demonstrating Efficacy of Plenadren® (Hydrocortisone, Modified Release Tablet) in Adrenal Insufficiency Published in the Journal of Clinical Endocrinology and Metabolism 5Pivotal Data Demonstrating Efficacy of Plenadren® (Hydrocortisone, Modified Release Tablet) in Adrenal Insufficiency Published in the Journal of Clinical Endocrinology and Metabolism 6
(Date:5/25/2015)... Join Fiona's Soccer Camp at Novato High School's ... Irish National Player, Fiona O'Sullivan will be on site to ... her coaching style. Fiona has three camps running this summer ... at Lynwood Elmentary School (June 15-19) and Hill Recreation Center ... 6th, 2015 - 1:00-3:00pm. Bring a Soccer Ball, Cleats and ...
(Date:5/25/2015)... 2015 Decora Preset 60 Minute Countdown ... available on ‘The Hardware City.’ The product helps in automatically ... a time and the related electronic device is automatically turned ... of the company said, “We are glad that this amazing ... can buy Countdown Timer Switch in just a few clicks. ...
(Date:5/24/2015)... For people who are keen on the Enterokinase ... Research Report would be an useful report to refer ... present market scenario of this industry. The report also ... of this industry. The report summarizes key statistics of ... in this industry. The report is a valuable source ...
(Date:5/24/2015)... May 24, 2015 The federal ... http://www.testosteronelawsuithub.com/ ) has scheduled its next monthly Case ... multidistrict litigation. According to court documents filed in ... the Conference will be convened on June 2, ... Therapy Product Liability Litigation - MDL No. 2545) ...
(Date:5/24/2015)... WI (PRWEB) May 24, 2015 ... Health System CEO - The ... and honored at the fourth annual ... April 15 at Geneva National in ... school): ,     -Badger High School,         Jonathan ...
Breaking Medicine News(10 mins):Health News:US Sports Camps and Nike Soccer Camps Offer Complimentary Instructional Clinic with Fiona's Soccer Camp 2Health News:Leviton's Decora 60 Minute Countdown Timer Available On ‘The Hardware City’ 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2
... million breast cancer survivors have a lifetime risk for ... the limbs and impacts physical and psychosocial health. Second ... most dreaded effect of breast cancer treatment. In a ... risk of developing lymphedema is 40 percent to 60 ...
... which is acupuncture performed by a licensed physician trained ... for pain control. Richard Niemtzow, MD, PhD, MPH, Editor-in-Chief ... www.liebertpub.com/acu ) and the official journal of the American ... these efforts in the military. , The technique ...
... Society has worked out new guidelines for the diagnosis ... Malignant melanoma is responsible for 90% of deaths from ... last 30 years and UV radiation is thought to ... , Claus Garbe of Tbingen University and his ...
... effects our health so what influences our decisions to adopt ... like doctors and counsellors do and say what they do? ... workplace, the internet, and community in which we live be ... with addiction? How can schools promote healthy living? What could ...
... desmoteplase,s poor showing, researchers say , , THURSDAY, Dec. 18 (HealthDay ... of the vampire bat has failed to reduce stroke damage ... called desmoteplase, remains alive, experts say, because the study may ... "The sample size was underpowered to detect any benefit," said ...
... Partner in Madrid, Spain has developed a creative solution of ... encourage discussions between medical professionals. , ... ... Scala , the leading provider of end-to-end solutions for the ...
Cached Medicine News:Health News:Obesity increases lymphedema risk for breast cancer survivors 2Health News:New Year starts with focus on healthy living 2Health News:New Year starts with focus on healthy living 3Health News:Bat Saliva-Based Stroke Drug Disappoints in Trial 2Health News:Bat Saliva-Based Stroke Drug Disappoints in Trial 3Health News:Medical Congresses Employ Interactive Digital Posters to Deliver Dynamic Content to Medical Professionals 2Health News:Medical Congresses Employ Interactive Digital Posters to Deliver Dynamic Content to Medical Professionals 3Health News:Medical Congresses Employ Interactive Digital Posters to Deliver Dynamic Content to Medical Professionals 4Health News:Medical Congresses Employ Interactive Digital Posters to Deliver Dynamic Content to Medical Professionals 5
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: